Table 1.

Drugs tested in the panel of 25 NSCLC cell lines

Two-way ANOVA (MUT vs. WT)
DrugTargetDose range (nmol/L)PSignificance
TrametinibMEK1,250-9.760.0031**
PD-0325901MEK1,250-9.760.0053**
SelumetinibMEK1,250-9.760.0181*
CI-1040MEK1,250-9.760.0123*
AZ628RAF2,500-19.50.0037**
RAF/MEK/ERKL779450RAF20,000-1560.0274*
PLX4720RAF20,000-1560.0116*
GDC-0879RAF20,000-1560.0483*
SorafenibRAF10,000-780.0285*
ZM336372RAF20,000-1560.0924ns
GW5074RAF10,000-780.1282ns
SB590885RAF2,0000-1560.2135ns
GDC0941PI3K5,000-390.6078ns
PIK-90PI3K2,500-19.50.7292ns
PIK-75PI3K (p110α)250-1.950.2477ns
NVP-BEZ235PI3K/mTOR250-1.950.2202ns
PF-04691502PI3K/mTOR5,000-390.9707ns
PI3K/AKT/mTORPP242mTOR (kinase)2,0000-1560.6741ns
AZD8055mTOR (kinase)5,000-390.5811ns
EverolimusmTOR (rapalog)5,000-390.8585ns
TemsirolimusmTOR (rapalog)5,000-390.9338ns
Akti- 1/2AKT20,000-1560.2065ns
MK-2206AKT20,000-1560.9727ns
NVP-AEW541IGF1R5,000-390.0042**
OSI-906IGF1R10,000-780.0041**
BMS-754807IGF1R5,000-390.0014**
RTKPicropodophyllinIGF1R1,000-7.80.4921ns
IGF-1R Inhibitor IIIGF1R20,000-1560.5752ns
ErlotinibEGFR5,000-390.1073ns
GefitinibEGFR5,000-390.0139ns
17-AAGHSP90500-3.90.0355*
17-DMAGHSP90500-3.90.0401*
BIIB021HSP90500-3.90.1456ns
NVP-AUY922HSP90500-3.90.5857ns
BX-795TBK15,000-390.1786ns
PF-02341066c-Met5,000-390.0479*
SU11274c-Met5,000-390.4032ns
BortezomibProteasome250-1.950.406ns
MG-132Proteasome5,000-390.3896ns
PSIProteasome2,500-19.50.8714ns
DoxorubicinTopoisomerase1,125-8.90.1158ns
TopotecanTopoisomerase2,500-19.50.4927ns
OTHERBMS-345541IKK-β20,000-1560.3172ns
SC-514IKK-220,000-1560.9998ns
CAY10576IKK-e20,000-1560.5216ns
5Z-7-OxozeaenolTAK1 (NF-κB)20,000-1560.2505ns
FasudilROCK20,000-1560.8516ns
Y-27632ROCK20,000-1560.9011ns
DocetaxelMicrotubule10-0.0780.3609ns
MK2a InhibitorMK25,000-390.1352ns
DeguelinMT-bioenergetics20,000-1560.7901ns
10058-F4c-Myc20,000-1560.2072ns
PF-573,228FAK20,000-1560.4752ns
GDC-0449Hedgehog pathway20,000-1560.6057ns
DasatinibSRC5,000-390.1236ns

NOTE: Cell viability was measured across an 8-point titration range. Two-way ANOVA was used to examine significant differences in sensitivity between KRAS-mutant (MUT) and wild-type (WT) cells. Only primary drug targets are indicated.

Abbreviation: ns, not significant.